<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04056247</url>
  </required_header>
  <id_info>
    <org_study_id>OH-HRPP-001</org_study_id>
    <nct_id>NCT04056247</nct_id>
  </id_info>
  <brief_title>Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments</brief_title>
  <acronym>PROPHETIC</acronym>
  <official_title>PROPHETIC - Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OncoHost Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OncoHost Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will develop an algorithm of identifying patients with stage IV NSCLC and Melanoma
      who could benefit from cancer treatment they receive.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this research study is to develop an algorithm that predicts the patient's
      treatment outcome.This algorithm will serve as a tool for physicians when making treatment
      decisions, specifically for stage IV NSCLC and malignant melanoma patients receiving
      anti-cancer treatments. The investigators also aim to identify the metabolic pathways that
      could lead to better therapeutic options. The patients will be given their treatment
      according to the institute's standard of care. The patients will provide two blood samples
      and clinical data will be collected from their medical records.

      In the first part of the trial, the data obtained from the blood samples and the medical
      records of the patients will be used to develop the prediction algorithm, and in the second
      part of the trial, the algorithm will be validated by comparing the objective response rate
      of the patients to the theoretical response prediction of the algorithm.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (ORR) at 3 months</measure>
    <time_frame>At 3 months after therapy</time_frame>
    <description>ORR as defined by RECIST 1.1 or other validated method for ORR evaluation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall response rate (ORR) at 6 months</measure>
    <time_frame>At 6 months after therapy</time_frame>
    <description>ORR as defined by RECIST 1.1 or other validated method for ORR evaluation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in the blood levels of different proteins that represent the host response</measure>
    <time_frame>At baseline (pre-therapy) and after 1st dose administration (post therapy)</time_frame>
    <description>Changes in Blood levels of proteins representing the Host response</description>
  </primary_outcome>
  <other_outcome>
    <measure>Adverse Events (AE)</measure>
    <time_frame>At second blood collection, 3 months and 6 months after treatment</time_frame>
    <description>AE, as reported by the patients</description>
  </other_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Stage IV Non-small Cell Lung Cancer</condition>
  <condition>Stage IV Malignant Melanoma</condition>
  <arm_group>
    <arm_group_label>NSCLC stage IV Immunotherapy and Chemotherapy</arm_group_label>
    <description>Patients with newly diagnosed stage IV NSCLC treated with Immunotherapy or Immunotherapy and Chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NSCLC stage IV 2nd line immunotherapy</arm_group_label>
    <description>Patients with NSCLC stage IV treated with Immunotherapy at 2nd line or consecutive lines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NSCLC stage IV chemotherapy and radiotherapy</arm_group_label>
    <description>Patients with Stage IV NSCLC treated with Chemotherapy and Chemotherapy + Radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MM stage IV</arm_group_label>
    <description>Patients with stage IV malignant melanoma treated with Immunotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MM stage IIIb-d</arm_group_label>
    <description>Patients with stage IIIb-d malignant melanoma treated with Immunotherapy as adjuvant therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Plasma sample collection</intervention_name>
    <description>Collect two plasma samples</description>
    <arm_group_label>MM stage IV</arm_group_label>
    <arm_group_label>NSCLC stage IV 2nd line immunotherapy</arm_group_label>
    <arm_group_label>NSCLC stage IV Immunotherapy and Chemotherapy</arm_group_label>
    <arm_group_label>NSCLC stage IV chemotherapy and radiotherapy</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma samples.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        1. Patients with newly diagnosed stage IV NSCLC treated with Immunotherapy or
             Immunotherapy + Chemotherapy.

          2. Patients with NSCLC stage IV treated with Immunotherapy at 2nd line or consecutive
             lines.

          3. Patients with Stage IV NSCLC treated with Chemotherapy and Chemotherapy +
             Radiotherapy.

          4. Patients with stage IV malignant melanoma treated with Immunotherapy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cancer patients with stage IV NSCLC or stage IV malignant melanoma

          -  Patient must have at least one measurable lesion and the relevant images in order to
             enable assessment of response

          -  ECOG PS - 0/1-2

          -  Normal hematologic, renal and liver function:

               1. Absolute neutrophil count higher than 1500/mm3

               2. Platelets count higher than 100,000/mm3

               3. haemoglobin higher than 9 g/dL

               4. Creatinine concentration ≤1.4 mg/dL, or creatinine clearance higher than 40
                  mL/min

               5. Total bilirubin lower than 1.5 mg/dL, ALT and AST levels ≤ 3 times above the
                  upper normal limit.

        Exclusion Criteria:

          -  Concurrent and/or other active malignancy that has required systemic treatment within
             2 years of first dose of study drug

          -  Generalized impairment or mental incompetence that would render the patient unable to
             understand his/her participation in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mor Moskovitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rambam Health Care Campus</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michal Lotem, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jair Bar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheba Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maya Gottfried, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Meir Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abed Agbaria, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bnai Zion Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ido Wolf, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tel-Aviv Sourasky Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mahmud Abu-Amana, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>haemek medical center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rivka Katsenelson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaplan Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexander Yakobson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Soroka University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Noam Asna, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barzilai Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alona Zer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rabin Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ella Tepper, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assuta Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Galit Yahalom, Ph.D.</last_name>
    <phone>97248537554</phone>
    <email>galit@oncohost.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shani Raveh, Ph.D.</last_name>
    <phone>97248537554</phone>
    <email>shani@oncohost.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Assuta Medical Cetner</name>
      <address>
        <city>Tel Aviv</city>
        <state>HaMerkaz</state>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ella Tepper, MD</last_name>
      <phone>972-525282726</phone>
      <email>ellat@assuta.co.il</email>
    </contact>
    <investigator>
      <last_name>Ella Tepper, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Haemek Medical Center</name>
      <address>
        <city>Afula</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mahmud Abu-Amana, MD</last_name>
      <phone>972-4-6495686</phone>
      <email>mahmud_ab@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Mahmud Abu-Amana, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gil Bar-Sela, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kamel Mahmid, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olga Vornicova, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barzilai Medical Center</name>
      <address>
        <city>Ashkelon</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Noam Asna, Md</last_name>
      <phone>972-8-6745378</phone>
      <email>noama@barzi.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Noam Asna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Soroka Medical Center</name>
      <address>
        <city>Be'er Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexander Yakobson, MD</last_name>
      <email>Alexy@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Alexander Yakobson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bnai Zion Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abed Agbaria, MD</last_name>
      <phone>972-4835-9016</phone>
      <email>abed.agbarya@b-zion.org.il</email>
    </contact>
    <investigator>
      <last_name>Abed Agbaria, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ella Kozliner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yelena Shechtman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mor, MD</last_name>
      <phone>9724-7776700</phone>
      <email>m_moskovitz@rambam.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Mor Moskovitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mira Wollner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mahamoud Abu Amna, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Talia Shentzer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hadassah Medcial Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michal Lotem, Prof.</last_name>
      <phone>972-2677-6781</phone>
      <email>mlotem@hadassah.org.il</email>
    </contact>
    <investigator>
      <last_name>Michal Lotem, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hovav Hovav Nechushtan, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonathan Cohen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yakir Rottenberg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Avner Mordechay, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Meir medical center</name>
      <address>
        <city>Kfar Saba</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maya Gottfried, MD</last_name>
      <phone>972-9747-2414</phone>
      <email>Maya.Gottfried@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Maya Gottfried, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Natalie Maimon-Rabinovich, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Moshe Mishaly, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petah tikva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alona Zer, MD</last_name>
      <phone>972-39378146</phone>
      <email>Alonaz@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Alona Zer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hendler Daniel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaplan Medical Center</name>
      <address>
        <city>Reẖovot</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rivka Katsenelson, MD</last_name>
      <phone>972-89441087</phone>
      <email>Rivka_K@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Rivka Katsenelson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Assuta Medical Cetner</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ella Tepper, MD</last_name>
      <phone>972-3-7896541</phone>
      <email>ellat@assuta.co.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ido Wolf, Prof.</last_name>
      <phone>972-36925623</phone>
      <email>idow@tlvmc.gov.il</email>
    </contact>
    <investigator>
      <last_name>Ido Wolf, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>MOR MIODOVNIK, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>ARI RAPHAEL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>OFER MERIMSKY, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>SHULIM SHPIGEL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>FREDERIC SINAI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>HAGAI LIGUMSKY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shiba medical center</name>
      <address>
        <city>Tel HaShomer</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jair Bar, MD</last_name>
      <phone>972-3530-7096</phone>
      <email>Yair.Bar@sheba.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Jair Bar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amir Onn, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sameh Daher, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Akram Saad, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shirley Grinberg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ronen Shtoff, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Smadar Bauer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tamar Beller, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Shaked Y. Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects. Nat Rev Clin Oncol. 2016 Oct;13(10):611-26. doi: 10.1038/nrclinonc.2016.57. Epub 2016 Apr 26. Review.</citation>
    <PMID>27118493</PMID>
  </reference>
  <reference>
    <citation>Shaked Y, Kerbel RS. Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy. Cancer Res. 2007 Aug 1;67(15):7055-8. Review.</citation>
    <PMID>17671170</PMID>
  </reference>
  <reference>
    <citation>Shaked Y, Bocci G, Munoz R, Man S, Ebos JM, Hicklin DJ, Bertolini F, D'Amato R, Kerbel RS. Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic drug activity and determine optimal biologic dose. Curr Cancer Drug Targets. 2005 Nov;5(7):551-9. Review.</citation>
    <PMID>16305351</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>August 11, 2019</study_first_submitted>
  <study_first_submitted_qc>August 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2019</study_first_posted>
  <last_update_submitted>May 11, 2020</last_update_submitted>
  <last_update_submitted_qc>May 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

